Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting
Immunotherapy Advances · 31.12.2025 · 6 (1)
DOI: 10.1093/immadv/ltag011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 26.06.2026. Verfasst von Luman Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China. Die Arbeit nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The field of immunology is increasingly intersecting with molecular biology, metabolic biology, and neurobiology (Zhu et al, A neuroimmune circuit mediates cancer cachexia-associated apathy. Science 2025;388:eadm8857; Jaschke et al, Gut-to-brain signaling restricts dietary protein intake during recovery from catabolic states. Cell 2025;188:7481–7494.e16; Zheremyan et al, Regulatory B cells: changing the landscape of immunoregulation and immunotherapy. Cytokine Growth Factor Rev 2025;86:121–36), marking a shift beyond traditional research approaches toward a more comprehensive understanding of the immune system. Central to this integrated perspective is the growing recognition that B cells are not only antibody producers, but also multifunctional cells dynamically modulated by their microenvironment. This comprehensive synthesis of recent research illuminates the dual nature of regulatory B cells (Bregs) as pivotal orchestrators of immune homeostasis. We examine how Bregs, governed by complex metabolic cues, neural signaling pathways, and local tissue microenvironments, can either suppress pathological inflammation or be co-opted to drive disease progression in autoimmunity, cancer, and allergic conditions. Understanding these microenvironmental determinants of Breg function is particularly critical for developing next-generation prognostic tools and targeted therapeutic strategies that effectively modulate B cell activity in various disease states.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
- Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
- Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
ORCID-Profile: Luman Wang, Ronghua Liu, Yiwei Chu
Zitieren
APA
Wang, L., Liu, R., & Chu, Y. (2025). Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag011
Vancouver
Wang L, Liu R, Chu Y. Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag011
BibTeX
@article{Wang2025,
author = {Wang, Luman and Liu, Ronghua and Chu, Yiwei},
title = {Harnessing the duality of regulatory B cells: from identification of characteristic molecules to therapeutic targeting},
journal = {Immunotherapy Advances},
year = {2025},
volume = {6},
number = {1},
doi = {10.1093/immadv/ltag011}
}
EUVIMED